Kodiak Sciences Inc. (KOD) Income Statement

The company remains pre-revenue, with zero product sales across all reported quarters. The sequential increase in net losses from $43.0M in 2024Q1 to $65.6M in 2026Q2 reflects a 52.6% expansion in quarterly deficit, driven primarily by rising R&D expenditures. This suggests the company is in an intensive development phase, likely funding late-stage clinical trials, with no near-term revenue visibility.

R&D is the primary cost driver, accounting for roughly 84% of total operating expenses in 2026Q2, up from 76% in 2024Q1. The surge in R&D spending suggests management is prioritizing clinical development, possibly for pivotal trials, which may explain the widening operating losses. SG&A has been relatively contained, fluctuating between $7.7M and $13.5M, implying disciplined overhead management despite the scaling of research activities.

With zero revenue, operating leverage is inherently negative; every dollar of R&D and SG&A directly reduces operating income. The operating margin is undefined, but the trend shows accelerating losses, suggesting that the company is scaling up investment without any offsetting income. This pattern is typical for late-stage biotechs, but investors should monitor whether the increased spending translates into clinical milestones that could support future commercialization.

The 2025Q4 quarter stands out with a sharp increase in R&D (from $43.6M in 2025Q1 to $45.5M) and a dramatic spike in SBC to $27.3M, nearly double the typical quarterly level. This suggests a strategic acceleration in development activities, possibly initiating a large clinical trial or scaling up manufacturing. The elevated SBC may indicate a significant equity-based compensation event, such as executive retention grants, which could signal management's confidence in the pipeline but also raises dilution concerns.